#T-Cell_Therapy
LightNews LightNews
newsen.bsky.social
CAR T-Cell Therapy: A Revolutionary Shift in Acute Lymphoblastic Leukemia Treatment Prospects#USA#Las_Vegas#DelveInsight#CAR_T-cell_Therapy#Acute_Lymphoblastic_Leukemia
CAR T-Cell Therapy: A Revolutionary Shift in Acute Lymphoblastic Leukemia Treatment Prospects
The CAR T-Cell Therapy market for Acute Lymphoblastic Leukemia is projected to witness robust growth fueled by emerging treatments and an expanding pipeline through 2036.
third-news.com
August 12, 2026 at 4:07 PM
newsen.bsky.social
New LLS Docuseries Unveils Breakthroughs in CAR T-cell Therapy for Blood Cancer#United_States#Washington#CAR_T-cell_Therapy#Blood_Cancer#LLS
New LLS Docuseries Unveils Breakthroughs in CAR T-cell Therapy for Blood Cancer
The Leukemia & Lymphoma Society's new docuseries aims to empower blood cancer patients with knowledge about CAR T-cell therapy, featuring inspiring patient stories.
third-news.com
March 4, 2025 at 1:38 PM
newsen.bsky.social
PeproMene Bio's Groundbreaking Publication in The Lancet Showcases Promising CAR T-Cell Therapy for B-Cell Lymphomas#USA#Irvine#CAR_T-cell_Therapy#B-cell_Lymphoma#PeproMene_Bio
PeproMene Bio's Groundbreaking Publication in The Lancet Showcases Promising CAR T-Cell Therapy for B-Cell Lymphomas
PeproMene Bio has announced the publication of significant Phase 1 trial results in The Lancet demonstrating effective CAR T-cell therapy for B-cell lymphomas.
third-news.com
September 8, 2026 at 10:07 AM
newsen.bsky.social
PeproMene Bio's Breakthrough Cancer Therapy Shows Promising Phase 1 Trial Results Published in The Lancet#USA#Irvine#CAR_T-cell_Therapy#B-cell_Lymphoma#PeproMene_Bio
PeproMene Bio's Breakthrough Cancer Therapy Shows Promising Phase 1 Trial Results Published in The Lancet
PeproMene Bio recently published significant results in The Lancet, revealing their innovative CAR T-cell therapy's efficacy for treating B-cell lymphomas, even after prior treatment failures.
third-news.com
September 8, 2026 at 10:07 AM
newsen.bsky.social
The Emily Whitehead Foundation's 2026 Believe Ball: A Night to Celebrate Advanced Therapies and Patient Voices#CAR_T-cell_Therapy#Advanced_Therapies#Emily_Whitehead
The Emily Whitehead Foundation's 2026 Believe Ball: A Night to Celebrate Advanced Therapies and Patient Voices
This September, the 2026 Believe Ball will celebrate patient advocates and CAR T-cell therapy in Philadelphia, showcasing the impact of advanced therapies.
third-news.com
August 26, 2026 at 5:31 PM
newsen.bsky.social
CARsgen Therapeutics Unveils Promising Interim Results for 2026, Showcasing Groundbreaking Progress#CAR_T-cell_Therapy#Satri-cel#CARsgen_Therapeutics
CARsgen Therapeutics Unveils Promising Interim Results for 2026, Showcasing Groundbreaking Progress
Discover the latest interim results from CARsgen Therapeutics as they highlight major advancements in CAR T-cell therapies and financial stability.
third-news.com
August 19, 2026 at 12:24 AM
newsen.bsky.social
Stand Up To Cancer's Maverick Award: Honoring Young Researchers in Oncology#United_States#Los_Angeles#CAR_T-cell_Therapy#Stand_Up_To_Cancer#Caitlin_Zebley
Stand Up To Cancer's Maverick Award: Honoring Young Researchers in Oncology
Stand Up To Cancer acknowledges Dr. Caitlin Zebley with the prestigious Maverick Early Career Scientist Award for her outstanding cancer research. This grant supports innovations in CAR T-cell therapies for children.
third-news.com
August 6, 2026 at 12:09 PM
newsen.bsky.social
Study Reveals Safety and Quality in CAR T-Cell Therapy Regardless of Center Accreditation#United_States#CAR_T-cell_Therapy#Florida_Cancer_Specialists#Fort_Myers#Treatment_Access
Study Reveals Safety and Quality in CAR T-Cell Therapy Regardless of Center Accreditation
A recent study by Florida Cancer Specialists reveals that CAR T-cell therapy achieves similar quality and safety outcomes at both accredited and non-accredited centers, emphasizing access as vital.
third-news.com
May 28, 2026 at 3:24 PM
newsen.bsky.social
CU Anschutz Gates Institute Receives FDA Clearance for Innovative CAR T-Cell Therapy Targeting Leukemia#United_States#Acute_Myeloid_Leukemia#CAR_T-cell_Therapy#Aurora#CU_Anschutz_Institute
CU Anschutz Gates Institute Receives FDA Clearance for Innovative CAR T-Cell Therapy Targeting Leukemia
The Gates Institute at CU Anschutz has made history by receiving FDA clearance for a novel CAR T-cell therapy aimed at treating acute myeloid leukemia, representing a vital step in cancer care.
third-news.com
April 2, 2026 at 6:39 PM
newsen.bsky.social
Growth of the Cell Therapy Market: A Surge Driven by Chronic Disease Treatments and Innovative Technologies#India#Pune#Chronic_Disease#CAR-T#Cell_Therapy
Growth of the Cell Therapy Market: A Surge Driven by Chronic Disease Treatments and Innovative Technologies
The cell therapy market is set to exceed USD 17.15 billion by 2032, propelled by advancements in CAR-T therapy and the treatment of chronic diseases.
third-news.com
March 31, 2026 at 5:21 PM
newsen.bsky.social
Eurofins Viracor Unveils ExPeCT™ Assay for CAR T-Cell Monitoring in Cutting-Edge Immunotherapy#USA#CAR_T-cell_Therapy#Eurofins_Viracor#Lenexa#ExPeCT™
Eurofins Viracor Unveils ExPeCT™ Assay for CAR T-Cell Monitoring in Cutting-Edge Immunotherapy
Discover Eurofins Viracor's revolutionary ExPeCT™ anti-CD19 CAR T-cell assay, designed for real-time monitoring of CAR T-cell therapy efficiency.
third-news.com
March 26, 2026 at 3:42 PM
newsen.bsky.social
CARsgen Therapeutics Reveals Strong Performance and Future Outlook in 2025 Annual Results#China#Shanghai#CAR_T-cell_Therapy#Satri-cel#CARsgen_Therapeutics
CARsgen Therapeutics Reveals Strong Performance and Future Outlook in 2025 Annual Results
CARsgen Therapeutics Holdings Limited announces its 2025 annual results, highlighting significant milestones in CAR T-cell therapy advancements and strong financial performance.
third-news.com
March 6, 2026 at 12:09 PM
newsen.bsky.social
Pioneers of CAR T-Cell Therapy Honored with 2025 Merkin Prize#United_States#Cambridge#CAR_T-cell_Therapy#Broad_Institute#Merkin_Prize
Pioneers of CAR T-Cell Therapy Honored with 2025 Merkin Prize
Carl June, Bruce Levine, Isabelle Rivière, and Michel Sadelain are recognized for their groundbreaking work on CAR T-cell therapy, advancing cancer treatment.
third-news.com
October 31, 2025 at 6:05 PM
newsen.bsky.social
Significant Growth Projections for the CAR T-cell Therapy Market from 2025 to 2034#United_States#Las_Vegas#Cancer_Treatment#CAR_T-cell_Therapy#Miltenyi_Biomedicine
Significant Growth Projections for the CAR T-cell Therapy Market from 2025 to 2034
The CAR T-cell therapy market is set for substantial growth between 2025 and 2034, driven by research investments and innovative therapies targeting various cancers.
third-news.com
October 28, 2025 at 9:43 PM
newsen.bsky.social
Gilead Unveils Inspiring Documentary on CAR T-Cell Therapy Teamwork in Japan#Japan#Tokyo#Gilead_Sciences#T-Cell_Therapy#Kite_CAR_T
Gilead Unveils Inspiring Documentary on CAR T-Cell Therapy Teamwork in Japan
Gilead announces three impactful documentaries showcasing the passionate journey of healthcare professionals in CAR T-cell therapy across Japan.
third-news.com
August 21, 2025 at 4:30 AM
newsen.bsky.social
Addressing Issues in Accessing CAR T-Cell Therapy for Patients#USA#CAR_T-cell_Therapy#Florida_Cancer_Specialists#Fort_Myers#Lucio_Gordan
Addressing Issues in Accessing CAR T-Cell Therapy for Patients
Dr. Lucio Gordan sheds light on barriers to CAR T-cell therapy accessibility at the Mayo Clinic's 34th Annual Review. Challenges include costs and structural gaps.
third-news.com
August 4, 2025 at 2:34 PM
newsen.bsky.social
Porton Advanced and EVA Pharma Collaborate to Enhance CAR T-Cell Therapy Access in MEA Region#CAR_T-cell_Therapy#Egypt#Cairo#Porton_Advanced#EVA_Pharma
Porton Advanced and EVA Pharma Collaborate to Enhance CAR T-Cell Therapy Access in MEA Region
Porton Advanced Solutions and EVA Pharma have signed an MOU to enhance access to CAR T-cell therapies in the Middle East and Africa, boosting local manufacturing and technology transfer.
third-news.com
June 26, 2025 at 1:55 PM
newsen.bsky.social
CARsgen's Satri-cel: A Breakthrough in CAR T-Cell Therapy for Cancer#China#Shanghai#CAR_T-cell_Therapy#Satri-cel#CARsgen_Therapeutics
CARsgen's Satri-cel: A Breakthrough in CAR T-Cell Therapy for Cancer
CARsgen Therapeutics reveals significant findings on satricabtagene autoleucel, or 'satri-cel', presented at key global medical venues, highlighting efficacy in advanced cancer treatments.
third-news.com
June 2, 2025 at 12:24 AM
newsen.bsky.social
Kyverna Therapeutics CEO to Highlight Advancements at Jefferies Global Healthcare Conference#United_States#New_York#CAR_T-cell_Therapy#Kyverna_Therapeutics#KYV-101
Kyverna Therapeutics CEO to Highlight Advancements at Jefferies Global Healthcare Conference
Kyverna Therapeutics will showcase its cell therapy advancements, including innovative CAR T-cell treatments, during the upcoming Jefferies Global Healthcare Conference.
third-news.com
May 28, 2025 at 8:13 PM
newsen.bsky.social
CARsgen Therapeutics Secures Priority Review for Satri-cel in China#China#Shanghai#CARsgen#Satri-cel#T-Cell_Therapy
CARsgen Therapeutics Secures Priority Review for Satri-cel in China
CARsgen Therapeutics has received Priority Review for its CAR T-cell therapy, Satri-cel, targeting advanced gastric cancer in patients with limited treatment options.
third-news.com
May 28, 2025 at 4:22 AM
newsen.bsky.social
Innovators Awarded 2025 Merkin Prize for CAR T-cell Breakthroughs in Cancer Treatment#USA#Cambridge#CAR_T-cell_Therapy#Richard_N._Merkin_Prize#biomedical_innovation
Innovators Awarded 2025 Merkin Prize for CAR T-cell Breakthroughs in Cancer Treatment
The 2025 Merkin Prize honors pioneers of CAR T-cell therapy, recognizing their life-saving contributions to personalized cancer treatment.
third-news.com
May 21, 2025 at 4:33 PM
newsen.bsky.social
The Remarkable Growth of CAR T-Cell Therapy: Forecasts Reach $27.5 Billion by 2033#United_States#Chicago#CAR_T-cell_Therapy#Immunotherapy_Innovations#Hematologic_Cancers
The Remarkable Growth of CAR T-Cell Therapy: Forecasts Reach $27.5 Billion by 2033
The CAR T-cell therapy market is expected to skyrocket from $2.7 billion in 2025 to over $27.5 billion by 2033, fueled by innovations and increasing adoption rates.
third-news.com
March 26, 2025 at 2:12 PM
newsen.bsky.social
Porton Advanced Partners with Eureka Therapeutics to Enhance T-Cell Therapy Progression#United_States#Cranbury#T-Cell_Therapy#Porton_Advanced#Eureka_Therapeutics
Porton Advanced Partners with Eureka Therapeutics to Enhance T-Cell Therapy Progression
Porton Advanced collaborates with Eureka Therapeutics to expedite T-cell therapy development, leveraging advanced manufacturing capabilities.
third-news.com
March 19, 2025 at 2:28 PM
newsen.bsky.social
Strategic Partnership Between Swarm Oncology and Cellex to Advance T-Cell Therapies for Solid Tumors#London#United_Kingdom#Swarm_Oncology#Cellex#T-Cell_Therapy
Strategic Partnership Between Swarm Oncology and Cellex to Advance T-Cell Therapies for Solid Tumors
Swarm Oncology has partnered with Cellex Cell Professionals to enhance their T-cell therapies aimed at solid tumors, accelerating clinical advancements.
third-news.com
February 24, 2025 at 1:05 PM